1
|
van Stein RM, Aalbers AGJ, Sonke GS and
van Driel WJ: Hyperthermic intraperitoneal chemotherapy for ovarian
and colorectal cancer: A review. JAMA Oncol. 7:1231–1238.
2021.PubMed/NCBI View Article : Google Scholar
|
2
|
Chicago Consensus Working Group. The
Chicago consensus on peritoneal surface malignancies: Management of
ovarian neoplasms. Cancer. 126:2553–2560. 2020.PubMed/NCBI View Article : Google Scholar
|
3
|
Winter WE III, Maxwell GL, Tian C, Carlson
JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F and
McGuire WP: Gynecologic Oncology Group Study. Prognostic factors
for stage III epithelial ovarian cancer: A gynecologic oncology
group study. J Clin Oncol. 25:3621–3627. 2007.PubMed/NCBI View Article : Google Scholar
|
4
|
Vergote I, Tropé CG, Amant F, Kristensen
GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ,
Panici PB, et al: Neoadjuvant chemotherapy or primary surgery in
stage IIIC or IV ovarian cancer. N Engl J Med. 363:943–953.
2010.PubMed/NCBI View Article : Google Scholar
|
5
|
McCluggage WG, Lyness RW, Atkinson RJ,
Dobbs SP, Harley I, McClelland HR and Price JH: Morphological
effects of chemotherapy on ovarian carcinoma. J Clin Pathol.
55:27–31. 2002.PubMed/NCBI View Article : Google Scholar
|
6
|
Bhatt A, Kammar P, Sinukumar S, Parikh L,
Jumle N, Shaikh S and Mehta S: Total parietal peritonectomy can be
performed with acceptable morbidity for patients with advanced
ovarian cancer after neoadjuvant chemotherapy: Results from a
prospective multi-centric study. Ann Surg Oncol. 28:1118–1129.
2021.PubMed/NCBI View Article : Google Scholar
|
7
|
Bhatt A, Bakrin N, Kammar P, Mehta S,
Sinukumar S, Parikh L, Shaikh S, Mishra S, Mallaya M, Kepenekian V,
et al: Distribution of residual disease in the peritoneum following
neoadjuvant chemotherapy in advanced epithelial ovarian cancer and
its potential therapeutic implications. Eur J Surg Oncol.
47:181–187. 2021.PubMed/NCBI View Article : Google Scholar
|
8
|
Hynninen J, Lavonius M, Oksa S, Grénman S,
Carpén O and Auranen A: Is perioperative visual estimation of
intra-abdominal tumor spread reliable in ovarian cancer surgery
after neoadjuvant chemotherapy? Gynecol Oncol. 128:229–232.
2013.PubMed/NCBI View Article : Google Scholar
|
9
|
Baratti D, Kusamura S, Cabras AD and
Deraco M: Cytoreductive surgery with selective versus complete
parietal peritonectomy followed by hyperthermic intraperitoneal
chemotherapy in patients with diffuse malignant peritoneal
mesothelioma: A controlled study. Ann Surg Oncol. 19:1416–1424.
2012.PubMed/NCBI View Article : Google Scholar
|
10
|
Yokosu K, Tanabe H, Nomura S, Ozone H,
Saito M, Takano H and Okamoto A: Total parietal peritonectomy in
primary debulking surgery for advanced ovarian cancer. Gynecol
Oncol Rep. 37(100805)2021.PubMed/NCBI View Article : Google Scholar
|
11
|
van Dam GM, Themelis G, Crane LM, Harlaar
NJ, Pleijhuis RG, Kelder W, Sarantopoulos A, de Jong JS, Arts HJ,
van der Zee AG, et al: Intraoperative tumor-specific fluorescence
imaging in ovarian cancer by folate receptor-α targeting: First
in-human results. Nat Med. 17:1315–1319. 2011.PubMed/NCBI View
Article : Google Scholar
|
12
|
O'Shannessy DJ, Somers EB, Smale R and Fu
YS: Expression of folate receptor-α (FRA) in gynecologic
malignancies and its relationship to the tumor type. Int J Gynecol
Pathol. 32:258–268. 2013.PubMed/NCBI View Article : Google Scholar
|
13
|
Kalli KR, Oberg AL, Keeney GL,
Christianson TJ, Low PS, Knutson KL and Hartmann LC: Folate
receptor alpha as a tumor target in epithelial ovarian cancer.
Gynecol Oncol. 108:619–626. 2008.PubMed/NCBI View Article : Google Scholar
|
14
|
Randall LM, Wenham RM, Low PS, Dowdy SC
and Tanyi JL: A phase II, multicenter, open-label trial of OTL38
injection for the intra-operative imaging of folate receptor-alpha
positive ovarian cancer. Gynecol Oncol. 155:63–68. 2019.PubMed/NCBI View Article : Google Scholar
|
15
|
Tanyi JL, Randall LM, Chambers SK, Butler
KA, Winer IS, Langstraat CL, Han ES, Vahrmeijer AL, Chon HS, Morgan
MA, et al: A phase III study of pafolacianine injection (OTL38) for
intraoperative imaging of folate receptor-positive ovarian cancer
(Study 006). J Clin Oncol. 41:276–284. 2023.PubMed/NCBI View Article : Google Scholar
|
16
|
Paul BK, Ihemelandu C and Sugarbaker PH:
Prior surgical score: An analysis of the prognostic significance of
an initial nondefinitive surgical intervention in patients with
peritoneal carcinomatosis of a colorectal origin undergoing
cytoreductive surgery and perioperative intraperitoneal
chemotherapy. Dis Colon Rectum. 61:347–354. 2018.PubMed/NCBI View Article : Google Scholar
|
17
|
Jacquet P and Sugarbaker PH: Clinical
research methodologies in diagnosis and staging of patients with
peritoneal carcinomatosis. Cancer Treat Res. 82:359–374.
1996.PubMed/NCBI View Article : Google Scholar
|
18
|
Sugarbaker PH: New standard of care for
appendiceal epithelial neoplasms and pseudomyxoma peritonei
syndrome? Lancet Oncol. 7:69–76. 2006.PubMed/NCBI View Article : Google Scholar
|
19
|
Parker N, Turk MJ, Westrick E, Lewis JD,
Low PS and Leamon CP: Folate receptor expression in carcinomas and
normal tissues determined by a quantitative radioligand binding
assay. Anal Biochem. 338:284–293. 2005.PubMed/NCBI View Article : Google Scholar
|
20
|
Bristow RE and Montz FJ: Complete surgical
cytoreduction of advanced ovarian carcinoma using the argon beam
coagulator. Gynecol Oncol. 83:39–48. 2001.PubMed/NCBI View Article : Google Scholar
|
21
|
Fanning J, Hilgers RD, Richards PK and
Hunt KD: Carbon dioxide laser vaporization of intestinal metastases
of epithelial ovarian cancer. Int J Gynecol Cancer. 4:324–327.
1994.PubMed/NCBI View Article : Google Scholar
|
22
|
Li S, Manning-Geist B, Gockley A, Ramos A,
Sisodia RC, Del Carmen M, Growdon WB, Horowitz N, Berkowitz R and
Worley M Jr: Use of ablation and ultrasonic aspiration at primary
debulking surgery in advanced stage ovarian, fallopian tube, and
primary peritoneal cancer. Int J Gynecol Cancer. 30:1052–1057.
2020.PubMed/NCBI View Article : Google Scholar
|